drugset / Trial / NCT00635713

Second Line Breast Cancer Trial

NCT00635713

Phase 3 Completed 588 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.

Timeline

Start
1997-05
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg
Subject Fulvestrant Small molecule 125 mg
Subject Fulvestrant Small molecule 250 mg